
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Bicycle Therapeutics plc	
(Name of Issuer)	
Ordinary shares, nominal value 0.01 per share	
(Title of Class of Securities)	
088786108	
(CUSIP Number)	
11/21/2024	
(Date of Event Which Requires Filing of this Statement)	
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:	
□ Rule 13d-1(b)☑ Rule 13d-1(c)	
Rule 13d-1(d)	

SCHEDULE 13G

CUSIP No. 088786108



E R P	Beneficially	0.00
	Owned by	Shared Voting Power
	Each Reporting Person	6
		3,452,330.00
		Sole Dispositive Power
	With:	7
		0.00
		Shared Dispositive
		8 Power
		3,452,330.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person
	9	3,452,330.00
		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	10	Check box if the aggregate amount in low (9) excludes certain shares (see instructions)
10		
		Percent of class represented by amount in row (9)
	11	• • • • • • • • • • • • • • • • • • • •
		7.3 %
	12	Type of Reporting Person (See Instructions)
		00

Comment for Type of Reporting Person: Based on 47,553,922 Ordinary Shares of the Issuer outstanding as of October 28, 2024, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on October 31, 2024.

SCHEDULE 13G

CUSIP No. 088786108

```
Names of Reporting Persons
1
           FORBION GROWTH II MANAGEMENT B.V.
           Check the appropriate box if a member of a Group (see instructions)
2
           (a)
            (b)
           Sec Use Only
3
           Citizenship or Place of Organization
4
           NETHERLANDS
              Sole Voting Power
              0.00
Number of
              Shared Voting Power
Shares
Beneficially
              3,452,330.00
Owned by
              Sole Dispositive Power
Each
Reporting
              0.00
Person
              Shared Dispositive
With:
            8 Power
              3,452,330.00
           Aggregate Amount Beneficially Owned by Each Reporting Person
           3,452,330.00
           Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10
```

11	Percent of class represented by amount in row (9)
11	7.3 %
	Type of Reporting Person (See Instructions)
12	
	OO
	nt for Type of Reporting Person: Based on 47,553,922 Ordinary Shares of the Issuer outstanding as of October 28, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on October 31, 2024.
SCHEI	DULE 13G
Item 1.	
	Name of issuer:
(a)	Bicycle Therapeutics plc
	Address of issuer's principal executive offices:
(b)	radiess of issuer's principal executive offices.
T. 0	Blocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, UK CB21 6GS
Item 2.	Name of person filing:
(a)	This statement is being filed by Forbion Growth Opportunities Fund II Cooperatief U.A. ("Forbion Growth II COOP") and Forbion Growth II Management B.V. ("Forbion Growth II"). Forbion Growth II COOP and Forbion Growth II are sometimes referred to collectively as the "Reporting Persons".
	Address or principal business office or, if none, residence:
(b)	The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.
(c)	Citizenship:
	Each of the Reporting Persons is organized under the laws of the Netherlands. Title of class of securities:
(d)	Ordinary shares, nominal value 0.01 per share
	CUSIP No.:
(e)	000706100
Item 3.	088786108 If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 780);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	■ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned:

Forbion Growth II COOP directly owns 3,452,330 Ordinary Shares of the Issuer. Forbion Growth II, the director of Forbion Growth II COOP, may be deemed to have voting and investment power over the shares held directly by Forbion Growth II COOP. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Percent of class:

- (b) The Ordinary Shares beneficially owned by the Reporting Persons represent approximately 7.3% of the outstanding Ordinary Shares, based on 47,553,922 Ordinary Shares of the Issuer outstanding as of October 28, 2024, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on October 31, 2024. %
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

3,452,330

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

3,452,330

- Item 5. Ownership of 5 Percent or Less of a Class.
- Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

The Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a "group" for purposes of Rule 13d-5 or for any other purpose.

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Forbion Growth Opportunities Fund II Cooperatief U.A.

Signature: /s/ V. van Houten and /s/ G.J. Mulder

V. van Houten and G.J. Mulder, Dirs. of FCPM III Sves B.V., Dir. of Forbion Growth II Mngmt B.V.,

Title: Dir. of Forbion Growth Opps Fund II Cooperatief

U.A.

12/19/2024 Date:

FORBION GROWTH II MANAGEMENT B.V.

Signature: /s/ V. van Houten and /s/ G.J. Mulder

V. van Houten and G.J. Mulder, Directors of

Name/Title: FCPM III Services B.V., Director of Forbion Growth II Management B.V.

12/19/2024 Date: